System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Ppublish 34 citations

PubMed: 35835580 DOI: 10.2967/jnumed.122.264106

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).

J Nucl Med 64(1):102-108

Authors: Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn

Affiliations

  • Relay Therapeutics, Cambridge, Massachusetts;.
  • Lymphoma Research Foundation, New York, New York.
  • King's College London and Guy's and St. Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom.
  • Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia.
  • Takeda Pharmaceutical Company Ltd. Cambridge, Massachusetts.
  • Bayer AG, Berlin, Germany.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine, New York, New York.
  • Department of Radiology, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, Columbia, New York.
  • Merck and Co, Inc. Kenilworth, New Jersey.
  • Deciphera Pharmaceuticals LLC, Waltham, Massachusetts.
  • LYSARC, Pierre Benite, France.
  • GSK, Collegeville, Pennsylvania.
  • Autolus Therapeutics, London, United Kingdom.
  • Calyx International, Billerica, Massachusetts.
  • Perlman Advisory Group LLC, Boynton Beach, Florida.
  • Merigold LLC, Branford, Connecticut.
  • Saint John's Cancer Institute and Tower Imaging Medical Group, Sherman Oaks, California.
  • KEOSYS Medical Imaging, Saint Herblain, France.
  • Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, Illinois; and.
  • TGEN/City of Hope and Imaging Endpoints Core Lab, Scottsdale, Arizona.

Abstract

Our objective was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for consistent application of the Lugano classification. Consensus was obtained through a series of meetings from July 2019 until September 2021 sponsored by the Pharma Imaging Network for Therapeutics and Diagnostics (PINTaD) as part of the PINTaD Response Criteria in Lymphoma Working Group (PRoLoG) consensus initiative. Consensus recommendations clarified technical considerations for PET/CT and diagnostic CT from the Lugano classification, including updating the FDG avidity of different lymphoma entities, clarifying the response nomenclature, and refining lesion classification and scoring, especially with regard to scores 4 and 5 and the X category of the 5-point scale. Combination of metabolic and anatomic responses is clarified, as well as response assessment in cases of discordant or missing evaluations. Use of clinical data in the classification, especially the requirement for bone marrow assessment, is further updated on the basis of lymphoma entities. Clarification is provided with regard to spleen and liver measurements and evaluation, as well as nodal response. Consensus recommendations are made to comprehensively address areas of inconsistency and ambiguity in the classification encountered during response evaluation by end users, and such guidance should be used as a companion to the 2014 Lugano classification.

MeSH

Nuclear Medicine, Hodgkin Disease, Classification, Lymphoma, Non-Hodgkin

Cited by